Bath & Body Works (NYSE:BBWI) Issues Q2 2025 Earnings Guidance

Bath & Body Works (NYSE:BBWI) updated its second quarter 2025 earnings guidance on Thursday. The company provided EPS guidance of 0.330-0.380 for the period, compared to the consensus EPS estimate of 0.420. The company issued revenue guidance of -, compared to the consensus revenue estimate of $1.6 billion.

Bath & Body Works Trading Down 1.5%

Shares of BBWI opened at $28.16 on Friday. The business’s 50-day moving average price is $30.07 and its 200 day moving average price is $33.94. The stock has a market capitalization of $6.00 billion, a P/E ratio of 6.87, a P/E/G ratio of 0.92 and a beta of 1.87. Bath & Body Works has a 1-year low of $24.96 and a 1-year high of $52.99.

Bath & Body Works (NYSE:BBWI) last released its earnings results on Thursday, May 29th. The company reported $0.49 earnings per share for the quarter, beating the consensus estimate of $0.47 by $0.02. The company had revenue of $1.40 billion for the quarter, compared to analysts’ expectations of $1.42 billion. Bath & Body Works had a negative return on equity of 44.03% and a net margin of 12.43%. The business’s revenue for the quarter was up 2.9% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.38 EPS. On average, research analysts predict that Bath & Body Works will post 3.3 earnings per share for the current year.

Bath & Body Works Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 20th. Investors of record on Friday, June 6th will be issued a $0.20 dividend. The ex-dividend date of this dividend is Friday, June 6th. This represents a $0.80 annualized dividend and a yield of 2.84%. Bath & Body Works’s dividend payout ratio (DPR) is currently 21.33%.

Bath & Body Works declared that its Board of Directors has approved a stock buyback program on Thursday, February 27th that allows the company to repurchase $500.00 million in outstanding shares. This repurchase authorization allows the company to repurchase up to 6.4% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company’s leadership believes its stock is undervalued.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on BBWI. Wells Fargo & Company boosted their price objective on Bath & Body Works from $40.00 to $44.00 and gave the company an “overweight” rating in a research report on Wednesday, May 14th. Citigroup upped their price target on Bath & Body Works from $36.00 to $42.00 and gave the company a “buy” rating in a research report on Tuesday, May 20th. The Goldman Sachs Group reduced their price objective on Bath & Body Works from $44.00 to $43.00 and set a “buy” rating on the stock in a research note on Friday. Morgan Stanley decreased their price target on Bath & Body Works from $49.00 to $43.00 and set an “overweight” rating on the stock in a report on Tuesday, May 6th. Finally, Raymond James decreased their price target on Bath & Body Works from $46.00 to $37.00 and set an “outperform” rating on the stock in a report on Thursday, April 17th. Four investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $42.00.

Hedge Funds Weigh In On Bath & Body Works

Several institutional investors and hedge funds have recently bought and sold shares of BBWI. Geneos Wealth Management Inc. boosted its holdings in shares of Bath & Body Works by 217.7% in the first quarter. Geneos Wealth Management Inc. now owns 1,169 shares of the company’s stock worth $35,000 after acquiring an additional 801 shares during the period. Intech Investment Management LLC purchased a new stake in Bath & Body Works during the first quarter valued at about $1,155,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in Bath & Body Works by 7.0% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 562,757 shares of the company’s stock valued at $17,063,000 after purchasing an additional 36,684 shares in the last quarter. Goldman Sachs Group Inc. raised its position in Bath & Body Works by 15.7% during the first quarter. Goldman Sachs Group Inc. now owns 645,970 shares of the company’s stock valued at $19,586,000 after purchasing an additional 87,529 shares in the last quarter. Finally, Royal Bank of Canada increased its holdings in shares of Bath & Body Works by 92.8% in the first quarter. Royal Bank of Canada now owns 59,877 shares of the company’s stock worth $1,815,000 after buying an additional 28,815 shares during the period. 95.14% of the stock is owned by institutional investors.

About Bath & Body Works

Bath & Body Works, Inc is a specialty retailers and home to America’s Favorite Fragrances, offering a breadth of exclusive fragrances for the body and home, including the selling collections for fine fragrance mist, body lotion and body cream, 3-wick candles, home fragrance diffusers and liquid hand soap.